Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations-Reference-Cited by-同舟云学术

Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations

Published:2017-03-06 Issue:20 Volume:8 Page:32626-32638
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Frega Stefano¹²,Lorenzi Martina¹,Fassan Matteo³,Indraccolo Stefano⁴,Calabrese Fiorella⁵,Favaretto Adolfo⁶,Bonanno Laura²,Polo Valentina¹²,Zago Giulia²,Lunardi Francesca⁵,Attili Ilaria¹²,Pavan Alberto¹²,Rugge Massimo³,Guarneri Valentina¹²,Conte PierFranco¹²,Pasello Giulia²

Affiliation:

1. Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy

2. Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy

3. Department of Medicine, Surgical Pathology Unit, University of Padova, Padova, Italy

4. Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IRCCS, Padova, Italy

5. Department of Cardio-Thoracic and Vascular Sciences, University of Padova, Padova, Italy

6. Medical Oncology, Azienda ULSS 9, Treviso, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review;Journal of Thoracic Oncology;2024-07

2. Investigation of age and smoking in NSCLC patients with uncommon EGFR mutations;Tuberk Toraks;2024-06-11

3. A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC;Frontiers in Oncology;2021-12-16

4. The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies;Expert Review of Molecular Diagnostics;2021-07-18

5. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis;Cancer Treatment and Research Communications;2021